Pasithea Therapeutics announced that the FDA has granted Orphan Drug Designation to its drug candidate PAS-004 for treating Amyotrophic Lateral Sclerosis (ALS), a rare and fatal neurodegenerative disease. This designation supports the development of PAS-004 by providing benefits like tax credits, fee exemptions, and potential market exclusivity. The company is currently conducting clinical trials for PAS-004 in other conditions and recently received a $1 million grant to study its efficacy and safety in ALS. This step highlights progress in addressing the significant unmet medical needs in ALS treatment.
Sodexo has secured a major global contract to provide catering services across more than 130 Meta sites in over 30 countries. This large-scale partnership includes diverse locations such as headquarters, campuses, data centers, and conference centers...
Ethereum rose 3.17% to $1,923.53, outperforming Bitcoin's modest 0.18% gain to $64,588.87, signaling an early rotation toward large-cap altcoins. Despite this, overall market activity slowed, with declines in DeFi, stablecoin, and derivatives trading...
Gabriel Holding A/S has agreed to sell its European FurnMaster furniture manufacturing operations, including subsidiaries in Poland and Lithuania, to Leggett & Platt for an initial price of approximately EUR 9 million, with a possible additional paym...
A Gaza resident raised over £55,000 on GoFundMe to support his family but faced issues as the platform cannot pay directly to Gaza, forcing funds through intermediaries who failed to deliver the full amount. This highlights a broader problem in human...
Crypto investigator ZachXBT criticized all current hardware wallets as insecure and unreliable for signing transactions or storing significant funds. He highlighted Ledger as particularly problematic due to frequent updates that disrupt basic functio...
